UT Health Sciences and UW-Madison Researchers Partner to Advance Potential Alphavirus Treatment
UT Health Sciences Researcher part of team studying antiviral drug for alphaviruses. The National Institute of Allergy and Infectious Diseases (NIAID) has funded a collaboration between the University of Wisconsin-Madison and the University Health Sciences (UT Health Sciences) to develop a drug candidate called BDGR-354, also known as Encephlavir, for potential human clinical trials. The project involves researchers Colleen B. Jonsson, PhD, Harriet Van Vleet Chair of Excellence in Virology, and Bernd Meibohm, PhD from the UT Health Sciences College of Pharmacy, leading a portion of the project alongside Jennifer E Golden, PhD of the Division of Pharmaceutical Sciences and Department of Chemistry at UW-Madison. Each investigator brings a different area of expertise to the project, including virology, pharmacology and medicinal chemistry. The ultimate goal is to develop BDGR.354 as a broad-spectrum treatment that could be used against multiple types of viruses, including Venezuelan equine encephalitis virus, Eastern equine equcephalitis, and Western equine. The drug was able to inhibit virulent strains of Venezuelan equecephalitis and Western Equine encephlavirs, but the next step is to determine if the drug is safe and suitable for human testing.
Publié : il y a 17 heures par Peggy Reisser dans Health Science
The team has received funding from the National Institute of Allergy and Infectious Diseases to conduct studies needed to prepare the drug candidate called BDGR-354, also known as Encephlavir, for pot... [5446 symbols]
